Dalteparin Versus Enoxaparin for Venous Thromboembolism Prophylaxis in Acute Spinal Cord Injury and Major Orthopedic Trauma Patients: ???DETECT??? Trial

Abstract

DETECT raises the hypothesis that dalteparin 5,000 units SC daily may not be clinically noninferior to enoxaparin 30 mg SC twice daily for VTE prophylaxis in this high-risk population. Until an adequately-powered, prospective noninferiority trial is performed, enoxaparin is supported by level 1 evidence and should be the prophylactic agent of choice.